| Literature DB >> 31770109 |
Shi Yong Neo1, Ying Yang1,2, Julien Record3, Ran Ma1, Xinsong Chen1, Ziqing Chen1, Nicholas P Tobin1, Emily Blake4, Christina Seitz5, Ron Thomas4, Arnika Kathleen Wagner6, John Andersson5, Jana de Boniface7,8, Jonas Bergh1, Shannon Murray9, Evren Alici6, Richard Childs10, Martin Johansson11, Lisa S Westerberg4, Felix Haglund1, Johan Hartman1,12, Andreas Lundqvist1.
Abstract
High levels of ecto-5'-nucleotidase (CD73) have been implicated in immune suppression and tumor progression, and have also been observed in cancer patients who progress on anti-PD-1 immunotherapy. Although regulatory T cells can express CD73 and inhibit T cell responses via the production of adenosine, less is known about CD73 expression in other immune cell populations. We found that tumor-infiltrating NK cells upregulate CD73 expression and the frequency of these CD73-positive NK cells correlated with larger tumor size in breast cancer patients. In addition, the expression of multiple alternative immune checkpoint receptors including LAG-3, VISTA, PD-1, and PD-L1 was significantly higher in CD73-positive NK cells than in CD73-negative NK cells. Mechanistically, NK cells transport CD73 in intracellular vesicles to the cell surface and the extracellular space via actin polymerization-dependent exocytosis upon engagement of 4-1BBL on tumor cells. These CD73-positive NK cells undergo transcriptional reprogramming and upregulate IL-10 production via STAT3 transcriptional activity, suppressing CD4-positive T cell proliferation and IFN-γ production. Taken together, our results support the notion that tumors can hijack NK cells as a means to escape immunity and that CD73 expression defines an inducible population of NK cells with immunoregulatory properties within the tumor microenvironment.Entities:
Keywords: Immunology; NK cells
Mesh:
Substances:
Year: 2020 PMID: 31770109 PMCID: PMC7269592 DOI: 10.1172/JCI128895
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808